Rick Doblin
👤 PersonAppearances Over Time
Podcast Appearances
You could think about it as this barrier, this permeable barrier, semi-permeable barrier between the conscious and the unconscious. And it all happens, we all know, at dreams, that material rises to our awareness at dreams. And it's like that with psychedelics. And so we just support whatever's emerging and people can go to some happy memories or to layers of trauma, whatever.
You could think about it as this barrier, this permeable barrier, semi-permeable barrier between the conscious and the unconscious. And it all happens, we all know, at dreams, that material rises to our awareness at dreams. And it's like that with psychedelics. And so we just support whatever's emerging and people can go to some happy memories or to layers of trauma, whatever.
You could think about it as this barrier, this permeable barrier, semi-permeable barrier between the conscious and the unconscious. And it all happens, we all know, at dreams, that material rises to our awareness at dreams. And it's like that with psychedelics. And so we just support whatever's emerging and people can go to some happy memories or to layers of trauma, whatever.
They're not forced to just focus on the trauma. So we have very low dropout rates. But the people that got the therapy without MDMA were able to make incredible progress. We also have what are called fidelity ratings, which is we videotape all the sessions and And then we have raters who are called adherence raters, and they look at, are people adhering to the therapeutic method?
They're not forced to just focus on the trauma. So we have very low dropout rates. But the people that got the therapy without MDMA were able to make incredible progress. We also have what are called fidelity ratings, which is we videotape all the sessions and And then we have raters who are called adherence raters, and they look at, are people adhering to the therapeutic method?
They're not forced to just focus on the trauma. So we have very low dropout rates. But the people that got the therapy without MDMA were able to make incredible progress. We also have what are called fidelity ratings, which is we videotape all the sessions and And then we have raters who are called adherence raters, and they look at, are people adhering to the therapeutic method?
And then that's called fidelity. We had over 90% fidelity, meaning that the therapists really were doing the same, whether it was placebo or not. So the results were outstanding in that way, and the side effects were very low. We had nobody commit suicide that received MDMA. That was one of the concerns. We had one woman tried to kill herself twice, but she was in the placebo group.
And then that's called fidelity. We had over 90% fidelity, meaning that the therapists really were doing the same, whether it was placebo or not. So the results were outstanding in that way, and the side effects were very low. We had nobody commit suicide that received MDMA. That was one of the concerns. We had one woman tried to kill herself twice, but she was in the placebo group.
And then that's called fidelity. We had over 90% fidelity, meaning that the therapists really were doing the same, whether it was placebo or not. So the results were outstanding in that way, and the side effects were very low. We had nobody commit suicide that received MDMA. That was one of the concerns. We had one woman tried to kill herself twice, but she was in the placebo group.
And we had another woman, such severe suicidal ideation, she checked herself into a hospital not to kill herself. She was also in the placebo group. Because when you help people with terrible trauma, it's difficult for them. And they're not able to really process. That's why they had long-term PTSD. So we demonstrated remarkable results. And yet the FDA said, we need more data. We need more data.
And we had another woman, such severe suicidal ideation, she checked herself into a hospital not to kill herself. She was also in the placebo group. Because when you help people with terrible trauma, it's difficult for them. And they're not able to really process. That's why they had long-term PTSD. So we demonstrated remarkable results. And yet the FDA said, we need more data. We need more data.
And we had another woman, such severe suicidal ideation, she checked herself into a hospital not to kill herself. She was also in the placebo group. Because when you help people with terrible trauma, it's difficult for them. And they're not able to really process. That's why they had long-term PTSD. So we demonstrated remarkable results. And yet the FDA said, we need more data. We need more data.
It has been. And I think one of the things that has kept me going was a dream. We've talked about dreams a little bit. It was a dream that I had when I was in my early 20s. So when I was 18, I had decided to focus my life on psychedelics. This was after I realized, oh, LSD is what my bar mitzvah should have been. And I was able to...
It has been. And I think one of the things that has kept me going was a dream. We've talked about dreams a little bit. It was a dream that I had when I was in my early 20s. So when I was 18, I had decided to focus my life on psychedelics. This was after I realized, oh, LSD is what my bar mitzvah should have been. And I was able to...